"Methylprednisolone Injections for the Carpal Tunnel Syndrome"
Annals Sep 3
http://annals.org/article.aspx?articleid=1733275
"Conclusion: Methylprednisolone injections for CTS have significant benefits in relieving symptoms at 10 weeks and reducing the rate of surgery 1 year after treatment, but 3 out of 4 patients had surgery within 1 year."

"Early and 1-Year Results From the ACCESS-EU, A Prospective, Multicenter, Nonrandomized Post-Approval Study of the MitraClip Therapy in Europe"
JACC Sep 2013
http://content.onlinejacc.org/article.aspx?articleid=1697385
"Conclusions  In the real-world, post-approval experience in Europe, patients undergoing the MitraClip therapy are high-risk, elderly patients, mainly affected by functional MR. In this patient population, the MitraClip procedure is effective with low rates of hospital mortality and adverse events."

"High-Density Lipoprotein Cholesterol, Size, Particle Number, and Residual Vascular Risk After Potent Statin Therapy" 
Circ Sep 3 (online)
http://circ.ahajournals.org/content/128/11/1189.abstract
"Conclusions—In the setting of potent statin therapy, HDL particle number may be a better marker of residual risk than chemically measured HDL-C or apoA-I. This has potential implications for evaluating novel therapies targeting HDL."

"Risk score for prediction of 10 year dementia risk in individuals with type 2 diabetes: a cohort study" 
Lancet Aug 20  
http://www.thelancet.com/journals/landia/article/PIIS2213-8587(13)70048-2/fulltext 
"Interpretation

To the best of our knowledge, this is the first risk score for the prediction of 10 year dementia risk in patients with type 2 diabetes mellitus. The risk score can be used to increase vigilance for cognitive deterioration and for selection of high-risk patients for participation in clinical trials."

"Risk of colorectal cancer after initiation of orlistat: matched cohort study"  BMJ
http://www.bmj.com/content/347/bmj.f5039 
"Conclusions
This study found no evidence of an increased risk of colorectal cancer after the initiation of orlistat. It is limited by the relatively short follow-up time, and the possibility of adverse effects of long term orlistat use on risk of colorectal cancer cannot be excluded."

"Behavioral and Dietary Risk Factors for Noncommunicable Diseases"
NEJM Sep 5
http://www.nejm.org/doi/full/10.1056/NEJMra1203528?query=featured_home 
"Except in eastern Europe and parts of Africa, mortality among adults has declined in most countries for decades.1 Lower rates of death from infectious diseases were the early driver of this improvement, but there have been subsequent declines in mortality from cardiovascular disease and some cancers.2,3 There have also been important trends in various cancers2 — for example, the rise and subsequent decline in lung-cancer incidence and mortality among men in many high-income countries, a decline in stomach-cancer incidence and mortality as economies develop, and the worldwide increase in breast-cancer incidence."

"Effects of a Fixed-Dose Combination Strategy on Adherence and Risk Factors in Patients With or at High Risk of CVD"  
JAMA Sep 4
http://jama.jamanetwork.com/article.aspx?articleid=1734704 
"Conclusions and Relevance   Among patients with or at high risk of CVD, use of an FDC strategy for blood pressure, cholesterol, and platelet control vs usual care resulted in significantly improved medication adherence at 15 months and statistically significant but small improvements in SBP and LDL-C."